Oncternal Therapeutics Stock Price

-0.02 (-1.5%)
Upgrade to Real-Time
Regular Market
Volume 270,773
Bid Price 1.30
Ask Price 1.32
News -
Day High 1.37


52 Week Range


Day Low 1.2627
Company Name Stock Ticker Symbol Market Type
Oncternal Therapeutics Inc ONCT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -1.5% 1.31 12:36:48
Open Price Low Price High Price Close Price Prev Close
1.34 1.2627 1.37 1.33
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
860 270,773 $ 1.31 $ 354,436 - 0.6902 - 4.63
Last Trade Time Type Quantity Stock Price Currency
12:36:48 100 $ 1.31 USD


Draw Mode:

Oncternal Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 69.71M 53.21M 52.70M $ - $ - -0.64 -1.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 237.50k 30.20%

more financials information »

Oncternal Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.111.401.071.21911,1930.2018.02%
1 Month1.231.400.991.14589,4010.086.5%
3 Months0.801.870.75631.361,204,9890.5163.75%
6 Months2.022.030.69021.33724,512-0.71-35.15%
1 Year3.354.630.69022.16661,912-2.04-60.9%
3 Years4.3010.560.69024.29939,630-2.99-69.53%
5 Years6.8710.560.69024.29887,110-5.56-80.93%

Oncternal Therapeutics Description

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Your Recent History
Oncternal ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now